KRAS Q61
|
CRC
|
KRAS Q61
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
KRAS Q61
|
CRC
|
KRAS Q61
|
CRC
|
selumetinib + RTB101 Sensitive: D – Preclinical
|
selumetinib + RTB101 Sensitive: D – Preclinical
|
KRAS Q61
|
CRC
|
KRAS Q61
|
CRC
|
RTB101 Sensitive: D – Preclinical
|
RTB101 Sensitive: D – Preclinical
|
KRAS Q61
|
CRC
|
KRAS Q61
|
CRC
|
selumetinib Sensitive: D – Preclinical
|
selumetinib Sensitive: D – Preclinical
|